|
JPS6322056A
(ja)
*
|
1986-04-30 |
1988-01-29 |
サンド・アクチエンゲゼルシヤフト |
オレフイン性化合物の製造法
|
|
NZ221717A
(en)
*
|
1986-09-10 |
1990-08-28 |
Sandoz Ltd |
Azaindole and indolizine derivatives and pharmaceutical compositions
|
|
US4897490A
(en)
*
|
1987-02-25 |
1990-01-30 |
Bristol-Meyers Company |
Antihypercholesterolemic tetrazole compounds
|
|
US4898949A
(en)
*
|
1987-02-25 |
1990-02-06 |
Bristol-Myers Company |
Intermediates for the preparation of antihypercholesterolemic tetrazole compounds
|
|
US5300252A
(en)
*
|
1987-03-13 |
1994-04-05 |
Fmc Corporation |
Ether free organometallic amide compositions
|
|
US5091378A
(en)
*
|
1987-05-22 |
1992-02-25 |
E. R. Squibb & Sons, Inc. |
Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
|
|
US4761419A
(en)
*
|
1987-12-07 |
1988-08-02 |
Warner-Lambert Company |
6-(((substituted)quinolinyl)ethyl)-and ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
|
|
US4868185A
(en)
*
|
1987-12-10 |
1989-09-19 |
Warner-Lambert Company |
6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
|
|
US4822799A
(en)
*
|
1988-01-27 |
1989-04-18 |
Sandoz Pharm. Corp. |
Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
|
|
NO890522L
(no)
*
|
1988-02-25 |
1989-08-28 |
Bayer Ag |
Substituerte imidazolinoner og imidazolinthioner.
|
|
IT1226726B
(it)
*
|
1988-07-29 |
1991-02-05 |
Zambon Spa |
Composti attivi come inibitori della biosintesi del colesterolo.
|
|
US5196440A
(en)
*
|
1988-07-29 |
1993-03-23 |
Zambon Group S.P.A. |
Compounds active as inhibitors of the cholesterol biosynthesis
|
|
US4870187A
(en)
*
|
1988-08-23 |
1989-09-26 |
Bristol-Myers Company |
Antihypercholesterolemic tetrazol-1-yl compounds
|
|
US5010205A
(en)
*
|
1988-08-23 |
1991-04-23 |
Bristol-Myers Company |
Antihypercholesterolemic tetrazol-1-yl intermediates
|
|
US5506219A
(en)
*
|
1988-08-29 |
1996-04-09 |
E. R. Squibb & Sons, Inc. |
Pyridine anchors for HMG-CoA reductase inhibitors
|
|
US5013749A
(en)
*
|
1988-10-03 |
1991-05-07 |
Glaxo Group Limited |
Imidazole derivatives and their use as hypercholesterolemia and hyperlipoproteinemia agents
|
|
IL91941A
(en)
*
|
1988-10-13 |
1994-10-21 |
Sandoz Ag |
Preparation of 6-Anoic and 7-Metanoic Fatty Acids and Their Substances and Intermediate Compounds and Acid 7-] 3-) 4-Fluorophenyl (-1-) 1- Methylethyl (a)
|
|
US5312828A
(en)
*
|
1989-06-14 |
1994-05-17 |
Finkelstein Joseph A |
Substituted imidazoles having angiotensin II receptor blocking activity
|
|
US5185351A
(en)
*
|
1989-06-14 |
1993-02-09 |
Smithkline Beecham Corporation |
Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
|
|
US5418250A
(en)
*
|
1989-06-14 |
1995-05-23 |
Smithkline Beecham Corporation |
Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
|
|
SG52330A1
(en)
*
|
1989-06-14 |
1998-09-28 |
Smithkline Beecham Corp |
Imidazolyl-alkenoic acids
|
|
US5106992A
(en)
*
|
1989-07-28 |
1992-04-21 |
E. R. Squibb & Sons, Inc. |
3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
|
|
US4970221A
(en)
*
|
1989-07-28 |
1990-11-13 |
E. R. Squibb & Sons, Inc. |
3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
|
|
EP0422895A1
(en)
*
|
1989-10-10 |
1991-04-17 |
Glaxo Group Limited |
Chemical compounds
|
|
US5177096A
(en)
*
|
1989-10-25 |
1993-01-05 |
Smithkline Beecham Corporation |
Substituted 5-((tetrazolyl)alkenyl)imidazoles and pharmaceutical methods of use thereof
|
|
IT1237792B
(it)
*
|
1989-12-21 |
1993-06-17 |
Zambon Spa |
Composti attivi come inibitori dell'enzima hmg-coa reduttasi
|
|
IT1237793B
(it)
*
|
1989-12-21 |
1993-06-17 |
Zambon Spa |
Composti attivi come inibitori dell'enzima hmg-coa reduttasi
|
|
US5049577A
(en)
*
|
1990-01-29 |
1991-09-17 |
E. R. Squibb & Sons, Inc. |
2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
|
|
CA2036192A1
(en)
|
1990-02-13 |
1991-08-14 |
Nicholas Meanwell |
Heterocyclic carboxylic acids and esters
|
|
US5011851A
(en)
*
|
1990-02-13 |
1991-04-30 |
Bristol-Myers Squibb Co. |
Imidazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
|
|
US5049578A
(en)
*
|
1990-03-09 |
1991-09-17 |
E. R. Squibb & Sons, Inc. |
1-aroyl or 1-acyl-2-2pyrrolidinyl-3,5-dihydroxy alkanoic and alkenoic acids, salts, esters and lactones
|
|
US5728842A
(en)
*
|
1992-06-30 |
1998-03-17 |
Smithkline Beecham Corporation |
Substituted imidazolyl-alkylthio-alkanoic acids
|
|
GB9213934D0
(en)
*
|
1992-06-30 |
1992-08-12 |
Smithkline Beecham Corp |
Chemical compounds
|
|
FR2696746B1
(fr)
*
|
1992-10-12 |
1994-11-18 |
Synthelabo |
Dérivés de l'acide benzèneborinique, leur préparation et leur utilisation comme intermédiaires de synthèse.
|
|
US20010006644A1
(en)
|
1997-07-31 |
2001-07-05 |
David J. Bova |
Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
|
|
AU5702201A
(en)
*
|
2000-04-13 |
2001-10-30 |
Mayo Foundation |
Abeta<sub>42</sub> lowering agents
|
|
US7276249B2
(en)
|
2002-05-24 |
2007-10-02 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
|
DK1385856T3
(da)
|
2001-04-11 |
2006-05-15 |
Bristol Myers Squibb Co |
Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
|
|
GEP20063908B
(en)
|
2001-10-18 |
2006-08-25 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
|
US7238671B2
(en)
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
|
US6806381B2
(en)
|
2001-11-02 |
2004-10-19 |
Bristol-Myers Squibb Company |
Process for the preparation of aniline-derived thyroid receptor ligands
|
|
EP1443919A4
(en)
|
2001-11-16 |
2006-03-22 |
Bristol Myers Squibb Co |
DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES
|
|
US6831102B2
(en)
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
|
WO2003094845A2
(en)
|
2002-05-08 |
2003-11-20 |
Bristol-Myers Squibb Company |
Pyridine-based thyroid receptor ligands
|
|
US7057046B2
(en)
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
|
EP1511467A1
(en)
|
2002-06-10 |
2005-03-09 |
Elan Pharma International Limited |
Nanoparticulate polycosanol formulations and novel polycosanol combinations
|
|
ATE469645T1
(de)
|
2002-10-23 |
2010-06-15 |
Bristol Myers Squibb Co |
Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
|
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
|
AU2003283769A1
(en)
|
2002-12-20 |
2004-07-14 |
Pfizer Products Inc. |
Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
|
|
TW200504021A
(en)
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
|
EP1603548A4
(en)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
|
|
US7557143B2
(en)
|
2003-04-18 |
2009-07-07 |
Bristol-Myers Squibb Company |
Thyroid receptor ligands
|
|
JP4752504B2
(ja)
|
2003-05-21 |
2011-08-17 |
株式会社ジェイ・エム・エス |
血液成分分離収容装置
|
|
US7459474B2
(en)
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
|
WO2005065069A2
(en)
*
|
2003-07-11 |
2005-07-21 |
Myriad Genetics, Inc. |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
|
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
|
EP2428516A1
(en)
|
2003-11-19 |
2012-03-14 |
Metabasis Therapeutics, Inc. |
Novel phosphorus-containing thyromimetics
|
|
PT1725234E
(pt)
|
2004-03-05 |
2013-03-04 |
Univ Pennsylvania |
Métodos com efeitos secundários reduzidos para tratamento de patologias ou doenças associadas a hiperlipidemia e hipercolesterolemia
|
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
|
WO2005108683A1
(en)
*
|
2004-04-29 |
2005-11-17 |
Keystone Retaining Wall Systems, Inc. |
Veneers for walls, retaining walls and the like
|
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
|
US7145040B2
(en)
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
CA2618985A1
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
AR051446A1
(es)
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
|
US7517991B2
(en)
|
2004-10-12 |
2009-04-14 |
Bristol-Myers Squibb Company |
N-sulfonylpiperidine cannabinoid receptor 1 antagonists
|
|
US7635699B2
(en)
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
|
US7589088B2
(en)
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
|
WO2006076597A1
(en)
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
|
US7314882B2
(en)
|
2005-01-12 |
2008-01-01 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
|
US7220859B2
(en)
|
2005-01-12 |
2007-05-22 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
|
US20060160850A1
(en)
|
2005-01-18 |
2006-07-20 |
Chongqing Sun |
Bicyclic heterocycles as cannabinoid receptor modulators
|
|
WO2006087630A2
(en)
*
|
2005-02-16 |
2006-08-24 |
Warner-Lambert Company Llc |
OXYPYRAZOLE HMG Co-A REDUCTASE INHIBITORS
|
|
EP1879881A2
(en)
|
2005-04-14 |
2008-01-23 |
Bristol-Myers Squibb Company |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
|
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
|
US7629342B2
(en)
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
|
US7317012B2
(en)
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
|
US7632837B2
(en)
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
|
US7452892B2
(en)
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
|
TW200726765A
(en)
|
2005-06-17 |
2007-07-16 |
Bristol Myers Squibb Co |
Triazolopyridine cannabinoid receptor 1 antagonists
|
|
US20070015832A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myriad Genetics, Incorporated |
Methods of treating overactive bladder and urinary incontinence
|
|
CA2615063A1
(en)
*
|
2005-07-22 |
2007-02-01 |
Myriad Genetics, Inc. |
High drug load formulations and dosage forms
|
|
US8618115B2
(en)
|
2005-10-26 |
2013-12-31 |
Bristol-Myers Squibb Company |
Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
|
|
EP2487154B1
(en)
|
2005-10-31 |
2013-10-16 |
Bristol-Myers Squibb Company |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
|
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
|
US8367112B2
(en)
|
2006-02-28 |
2013-02-05 |
Alkermes Pharma Ireland Limited |
Nanoparticulate carverdilol formulations
|
|
EP2021014A1
(en)
|
2006-05-26 |
2009-02-11 |
Brystol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
|
EP2046119A2
(en)
*
|
2006-07-07 |
2009-04-15 |
Myriad Genetics, Inc. |
Treatment of psychiatric disorders
|
|
US7968577B2
(en)
|
2006-11-01 |
2011-06-28 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
|
TW200904405A
(en)
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Pharmaceutical formulations containing an SGLT2 inhibitor
|
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
|
WO2009023059A2
(en)
|
2007-06-01 |
2009-02-19 |
The Trustees Of Princeton University |
Treatment of viral infections by modulation of host cell metabolic pathways
|
|
US20090011994A1
(en)
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
|
CN101808995A
(zh)
|
2007-07-27 |
2010-08-18 |
百时美施贵宝公司 |
新颖的葡糖激酶激活剂及其使用方法
|
|
ES2499018T3
(es)
|
2007-09-20 |
2014-09-26 |
Irm Llc |
Compuestos y composiciones como moduladores de la actividad de GPR119
|
|
EP2211856A4
(en)
*
|
2007-11-29 |
2011-02-09 |
Hospital For Sick Children |
COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDER
|
|
WO2010093601A1
(en)
|
2009-02-10 |
2010-08-19 |
Metabasis Therapeutics, Inc. |
Novel sulfonic acid-containing thyromimetics, and methods for their use
|
|
KR20110135411A
(ko)
|
2009-03-27 |
2011-12-16 |
브리스톨-마이어스 스큅 컴퍼니 |
Dpp-iv 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법
|
|
WO2011014520A2
(en)
|
2009-07-29 |
2011-02-03 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
|
CA2774573A1
(en)
|
2009-10-09 |
2011-04-14 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
|
CA3002948C
(en)
|
2009-11-13 |
2020-10-27 |
Astrazeneca Uk Limited |
Immediate release tablet formulations
|
|
CN102711739B
(zh)
|
2009-11-13 |
2015-12-16 |
阿斯利康(瑞典)有限公司 |
双层片剂
|
|
BR112012011274A2
(pt)
|
2009-11-13 |
2016-04-12 |
Astrazeneca Uk Ltd |
formulação de metformina de massa reduzida e sua combinação
|
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
|
EP2558461B1
(en)
|
2010-04-14 |
2015-12-02 |
Bristol-Myers Squibb Company |
Novel glucokinase activators and methods of using same
|
|
RU2596787C2
(ru)
|
2010-07-09 |
2016-09-10 |
БиЭйчВи ФАРМА, ИНК. |
Комбинированная система доставки с немедленным/замедленным высвобождением для лекарственных средств с коротким периодом полувыведения, в том числе для ремоглифлозина
|
|
US8697739B2
(en)
|
2010-07-29 |
2014-04-15 |
Novartis Ag |
Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
|
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
|
WO2014052619A1
(en)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Piperidine derivatives and compositions as modulators of gpr119 activity
|
|
TR201908247T4
(tr)
|
2012-11-20 |
2019-06-21 |
Lexicon Pharmaceuticals Inc |
Sodyum glikoz birlikte taşıyıcı 1 inhibitörleri.
|
|
WO2015027021A1
(en)
|
2013-08-22 |
2015-02-26 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
|
KR20170138570A
(ko)
|
2015-04-30 |
2017-12-15 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
대사 장애를 치료하기 위한 항-aP2 항체 및 항원 결합 물질
|
|
JOP20210009A1
(ar)
|
2018-07-19 |
2021-01-12 |
Astrazeneca Ab |
طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله
|
|
KR20210065974A
(ko)
|
2018-09-26 |
2021-06-04 |
렉시컨 파마슈티컬스 인코퍼레이티드 |
N-(1-((2-(디메틸아미노)에틸)아미노)-2-메틸-1-옥소프로판-2-일)-4-(4-(2-메틸-5-((2s,3r,4r,5s,6r)-3,4,5-트리히드록시-6-(메틸티오)테트라히드로-2h-피란-2-일)벤질)페닐)부탄아미드의 결정질 형태 및 그의 합성 방법
|
|
BR112023000808A2
(pt)
|
2020-07-29 |
2023-02-07 |
Amryt Pharmaceuticals Inc |
Lomitapida para uso em métodos para tratar hiperlipidemia e hipercolesterolemia em pacientes pediátricos
|
|
WO2025147589A1
(en)
|
2024-01-05 |
2025-07-10 |
Osanni Bio, Inc. |
Implants, compositions, and methods for treating retinal diseases and disorders
|